Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CARPINE versus OCUSERT PILO 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CARPINE versus OCUSERT PILO 40.
ISOPTO CARPINE vs OCUSERT PILO-40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.4 hours in healthy adults; clinically, this short half-life necessitates frequent dosing for sustained ocular effect.
Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is eliminated via urine within 24 hours, with about 20% as unchanged pilocarpine. Biliary/fecal elimination accounts for less than 5%.
Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%.
Category C
Category C
Ophthalmic Cholinergic Agonist
Ophthalmic Cholinergic Agonist